eureKARE (“the Company”), an innovative investment company for disruptive synthetic biology applications, today announces that it has co-led a EUR 5 million seed funding round in Biomemory which is advancing cutting-edge DNA data synthesis and storage solutions. The round was led by eureKARE and the French Tech Seed Fund, managed by Bpifrance, with the support of Paris Business Angels, Prunay Impact and existing investors. Biomemory, founded in 2021, is positioned at the crossroads of Biotechnology...